[A23-136] Alirocumab (hypercholesterolaemia) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-136
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Indication:
Paediatric patients 8 years of age and older with heterozygous familial hypercholesterolaemia
Result of dossier assessment:
- Patients in whom dietary and drug options for lipid lowering have not been exhausted: added benefit not proven
- Patients in whom dietary and drug options for lipid lowering have been exhausted: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A23-136_en
| Project no. | Title | Status |
|---|---|---|
| A18-74 | Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A15-47 | Alirocumab - Benefit assessment according to §35a Social Code Book V | Commission completed |